RankingsPricing
  1. US-listed companies
  2. INSMED Inc

INSMED IncINSM

Market cap
$11.1B
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Dec 31,
2011		Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023
Net loss-60-41-56-79-118-176-193-324-254-294-435-482-750
Depreciation-------459956
Amortization of intangible assets-------155555
Stock-based compensation expense23911161818262736465875
Loss on extinguishment of debt--------2---18--
Amortization of debt issuance costs-----00111-47
Accretion Expense--000010-----
Paid-in-Kind Interest-----------423
Other Noncash Expense-----------419
Finance lease amortization expense--------01123
Accretion of discount on marketable securities, net------------9
Noncash Operating Lease Expense--------10613129
Finance lease amortization expense--------01123
Change in fair value of deferred and contingent consideration liabilities----------7-2129
Noncash Operating Lease Expense--------10613129
Change in fair value of interest rate swap------------20
Change in fair value of deferred and contingent consideration liabilities----------7-2129
Accounts receivable0-1-----614-38612
Inventory-------7212117214
Prepaid expenses and other current assets00231-036936-3-2
Other assets--------166242520
Increase (Decrease) in Accounts Payable15-13-2344-530-85015
Other liabilities----------5-13-11
Net cash used in operating activities-30-31-----160-258-251-219-363-400-536
Change in fair value of interest rate swap------------20
Vertuis Bio, Inc.------------10
Adrestia Therapeutics Ltd------------76
Vertuis Bio, Inc.------------10
Adrestia Therapeutics Ltd------------76
Accounts receivable0-1-----614-38612
Inventory-------7212117214
Prepaid expenses and other current assets00231-036936-3-2
Other assets--------166242520
Increase (Decrease) in Accounts Payable15-13-2344-530-85015
Other liabilities----------5-13-11
Net cash used in operating activities-30-31-----160-258-251-219-363-400-536
Net loss-60-41-56-79-118-176-193-324-254-294-435-482-750
Depreciation-------459956
Amortization of intangible assets-------155555
Stock-based compensation expense23911161818262736465875
Loss on extinguishment of debt--------2---18--
Amortization of debt issuance costs-----00111-47
Accretion Expense--000010-----
Paid-in-Kind Interest-----------423
Other Noncash Expense-----------419
Finance lease amortization expense--------01123
Accretion of discount on marketable securities, net------------9
Noncash Operating Lease Expense--------10613129
Finance lease amortization expense--------01123
Change in fair value of deferred and contingent consideration liabilities----------7-2129
Noncash Operating Lease Expense--------10613129
Change in fair value of interest rate swap------------20
Change in fair value of deferred and contingent consideration liabilities----------7-2129
Accounts receivable0-1-----614-38612
Inventory-------7212117214
Prepaid expenses and other current assets00231-036936-3-2
Other assets--------166242520
Increase (Decrease) in Accounts Payable15-13-2344-530-85015
Other liabilities----------5-13-11
Net cash used in operating activities-30-31-----160-258-251-219-363-400-536
Change in fair value of interest rate swap------------20
Vertuis Bio, Inc.------------10
Adrestia Therapeutics Ltd------------76
Vertuis Bio, Inc.------------10
Adrestia Therapeutics Ltd------------76
Accounts receivable0-1-----614-38612
Inventory-------7212117214
Prepaid expenses and other current assets00231-036936-3-2
Other assets--------166242520
Increase (Decrease) in Accounts Payable15-13-2344-530-85015
Other liabilities----------5-13-11
Net cash used in operating activities-30-31-----160-258-251-219-363-400-536
Purchase of fixed assets10153431342671013
Purchase of marketable securities----------50100589
Maturities of marketable securities-----------75375
Cash acquired in asset acquisition------------3
Cash paid for Business Acquisition, net----------7--
Maturities of marketable securities-----------75375
PARI milestone upon regulatory approvals-------2-1---
Cash paid for Business Acquisition, net----------7--
Net cash used in investing activities3462-----3-15-42-7-64-35-224
Proceeds from Stock Options Exercised-02151392026222018
Proceeds from Issuance of Common Stock02667109223-378-261246270292152
Payment on extinguishment of 1.75% convertible senior notes due 2025-------3--13--
Payment of principal of 1.75% convertible senior notes due 2025----------225--
Proceeds from Convertible Debt-------450--575--
Proceeds from issuance of Term Loan-----------350-
Proceeds From Royalty Financing-----------150-
Payment of debt issuance costs-00000-14--16181
Other financing activities-----------1-1-
Payments of finance lease principal---------1--1
Net cash provided by financing activities              -045----381387285271613793168
Effect of exchange rates on cash and cash equivalents-----------1-1-0
Net (decrease) increase in cash and cash equivalents---------845184357-592
Cash paid for interest-------689111036
Income Taxes Paid, Net--193-00001222
Purchase of fixed assets10153431342671013
Purchase of marketable securities----------50100589
Maturities of marketable securities-----------75375
Cash acquired in asset acquisition------------3
Cash paid for Business Acquisition, net----------7--
Maturities of marketable securities-----------75375
PARI milestone upon regulatory approvals-------2-1---
Cash paid for Business Acquisition, net----------7--
Net cash used in investing activities3462-----3-15-42-7-64-35-224
Proceeds from Stock Options Exercised-02151392026222018
Proceeds from Issuance of Common Stock02667109223-378-261246270292152
Payment on extinguishment of 1.75% convertible senior notes due 2025-------3--13--
Payment of principal of 1.75% convertible senior notes due 2025----------225--
Proceeds from Convertible Debt-------450--575--
Proceeds from issuance of Term Loan-----------350-
Proceeds From Royalty Financing-----------150-
Payment of debt issuance costs-00000-14--16181
Other financing activities-----------1-1-
Payments of finance lease principal---------1--1
Net cash provided by financing activities              -045----381387285271613793168
Effect of exchange rates on cash and cash equivalents-----------1-1-0
Net (decrease) increase in cash and cash equivalents---------845184357-592
Cash paid for interest-------689111036
Income Taxes Paid, Net--193-00001222